Amarin Reports Data from REDUCE-IT® Showing VASCEPA®/VAZKEPA (Icosapent Ethyl) Significantly Reduces Ischemic Events in Patients with Prior Heart Attacks Presented in Late Breaking Science Session at ESC Congress 2021, Organized by the European Society

Submitted by amarin on Mon, 08/23/2021 - 07:15
Home
VASCEPA found in prespecified and post hoc analyses to reduce first and total primary endpoints by 26% and 35%, respectively, in patients with prior Myocardial Infarction DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced

Latest Clinical Research Evaluating VASCEPA®/VAZKEPA (Icosapent Ethyl) in Patients with Residual Cardiovascular Risk to be Presented at ESC Congress 2021, Organized by the European Society of Cardiology

Submitted by amarin on Mon, 08/16/2021 - 11:00
Home
Amarin-Supported Research and Analyses from International Academic Collaborators to Be Featured in Seven Presentations DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that new data that add to the growing body of

Amarin Reports Second Quarter and Six Month 2021 Financial Results and Provides Business Update

Submitted by amarin on Thu, 08/05/2021 - 10:00
Home
Commercial Launch of VAZKEPA in Europe on Track to Commence in September in Germany Filed Several Market Access Dossiers in Europe with Proposed Pricing of approximately €200 per Month New CEO, Karim Mikhail, to Host Conference Call Today at 7:30 a.m. ET DUBLIN, Ireland and BRIDGEWATER, N.J., Aug.
Subscribe to